Pfizer Getting $529 Per Course For Paxlovid Under US Contract; Did Merck Drive A Harder Bargain?

 
• By Cathy Kelly

US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.

The Costco Purchasing Model At Play? • Source: Alamy

More from Government Payers

More from Market Access